Nance-Horan syndrome

Thousands Could Benefit from New Take-at-Home Treatment for Advanced Prostate Cancer

7 days ago talkbio0Tagged enzalutamide, Malignant neoplasm of prostate, Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, talazoparib, Talzenna

prostate cancer; talazoparib; Talzenna; NICE; NHS; enzalutamide

UK cuts 2026 new-medicine rebate rate to 14.5% under VPAG

2 months ago talkbio0Tagged branded medicines, clawback rate, Drug Industry, drug price, Growth, Nance-Horan syndrome, rebate rate, United Kingdom, valproic acid glucuronide, Voluntary Scheme

United Kingdom; VPAG; Voluntary Scheme for Branded Medicines Pricing Access and Growth; rebate rate; clawback rate; new medicines; NHS; drug pricing; pharmaceutical industry; 2026

UK Proposes Raising Payment Scheme for Branded Medicines to Nearly 25% Amid Industry Pushback

4 months ago talkbio0Tagged Consultation, drugmakers, Industry, Nance-Horan syndrome, payment, pharmaceutical rebates, Pricing, Response process, spending, statutory scheme, UK

UK medicine pricing; NHS spending; statutory scheme; drugmakers; payment percentage; pharmaceutical rebates; industry response; consultation 2025

Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price

4 months ago talkbio0Tagged Antipsychotic Agents, Cholinergic Receptors, Cobenfy, drug price, launch, Myers, Nance-Horan syndrome, Prices, Schizophrenia, squibb, U.S., UK

Bristol Myers Squibb; Cobenfy; schizophrenia; UK launch; drug pricing; US list price; NHS; cholinergic receptors; antipsychotic; 2026

A Concerning Pattern: Pharma Mulls UK Divestments as Government Action Lags in Life Sciences

4 months ago talkbio0Tagged AstraZeneca, Biological Science Disciplines, drug price, drug spending, eli lilly, Government, Investments, Merck, Nance-Horan syndrome, pharmaceutical divestment, Policy, R&D, sanofi, UK

UK life sciences; pharmaceutical divestment; Merck; AstraZeneca; Sanofi; Eli Lilly; R&D investment; drug pricing; government policy; NHS drug spending

Eli Lilly Pauses UK Biotech Incubator Plans Amid Concerns Over NHS Drug Pricing

5 months ago talkbio0Tagged Biological Science Disciplines, biotech incubator, biotech industry, Eli, Eli Lilly, Gateway Labs, Government, Investments, Nance-Horan syndrome, Pauses, pharmaceutical innovation, UK

Eli Lilly; Gateway Labs; UK biotech incubator; pause; investment; NHS drug spending; life sciences; biotech industry; government funding; pharmaceutical innovation